H.C. Wainwright Reiterated Buy on Beam Therapeutics (BEAM) After BEAM-302 FDA Expedited Approval

Group 1 - Beam Therapeutics Inc. (NASDAQ:BEAM) is recognized as one of the best innovative stocks to buy, with H.C. Wainwright maintaining a Buy rating and a price target of $80, driven by advancements in its BEAM-302 therapy and an expedited FDA approval process for alpha-1 antitrypsin deficiency (AATD) [1][4] - The company plans to enroll approximately 50 additional patients at the ideal biologic dose in its ongoing Phase 1/2 trial, with new data expected to be reported by the end of Q1 2026 [3] - Beam Therapeutics concluded 2025 with around $1.25 billion in cash, cash equivalents, and convertible securities, extending its financial runway beyond 2029 to support the development of BEAM-302 and the upcoming risto-cel launch [4][5] Group 2 - Beam Therapeutics is a biotechnology firm focused on developing precision genetic medicines through its proprietary base-editing technology, with key investigational therapies including BEAM-101 and BEAM-302 [5]